摘要
Hepatocellular carcinoma(HCC)is a highly fatal disease,the mortality of which runs parallel to its incidence.Historically,viral hepatitis has been the major cause of HCC(1).Vaccine is available for hepatitis B virus(HBV)and a drug cocktail is effective in bringing down blood hepatitis C virus(HCV)level to zero.With successful application of mRNA vaccine for COVID-19,it is a matter of time before an effective vaccine for HCV is generated.Despite these positive advancements,the incidence of HCC is continuing to rise because of HCC development as a direct consequence of non-alcoholic steatohepatitis(NASH)caused by obesity(1).While viral hepatitis is waning in the Western countries,obesity is now a global problem,requiring impactful treatment regimen for HCC that can provide meaningful survival benefit.
基金
supported in part by The National Cancer Institute(NCI)Grants(Nos.1R01CA230561-01A1,1R01CA240004-01 and 1R01CA244993-01)
The National Institute of Diabetes and Digestive and Kidney Diseases(NIDDK)Grant(No.2R01DK107451-05).
